In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 80 days of free consultation


Differences during admission in patients with myocardial infarction with non-obstructive coronary arteries compared to myocardial infarction with obstructive lesions.

Session Poster Session 1

Speaker Barbara Izquierdo

Congress : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes - Epidemiology, Prognosis, Outcome
  • Session type : Poster Session
  • FP Number : P881

Authors : B Alcon Duran (Madrid,ES), J Lopez Pais (Santiago de Compostela,ES), D Galan Gil (Madrid,ES), B Izquierdo Coronel (Madrid,ES), MJ Espinosa Pascual (Madrid,ES), A Fraile Sanz (Madrid,ES), P Awamleh Garcia (Madrid,ES), C Moreno Vinues (Madrid,ES), JJ Alonso Martin (Madrid,ES)

B Alcon Duran1 , J Lopez Pais2 , D Galan Gil1 , B Izquierdo Coronel1 , MJ Espinosa Pascual1 , A Fraile Sanz1 , P Awamleh Garcia1 , C Moreno Vinues1 , JJ Alonso Martin1 , 1University Hospital Getafe - Madrid - Spain , 2University Hospital of Santiago de Compostela - Santiago de Compostela - Spain ,

On behalf: IMACORN investigators



Myocardial infarction (MI) with non-obstructive coronary arteries (MINOCA) means a non-negligible proportion of patients (pts) admitted for MI. However, there are still unsolved questions about this entity. The aim of our study is to analyse the differences between the MINOCA group compared with pts admitted for MI with obstructive coronary disease.


Analytical and observational study developed in a Universitary Hospital, which covers 220.000 individuals. From january-2016 until december-2018 we reviewed all the pts that were admitted for MI who underwent coronariography. MINOCA pts (defined according 2016 ESC Working Group position paper) compared with  MI pts with obstructive lesions.


One hundred and nine from 521 pts admitted for MI in whom a coronariography was performed fulfilled the 2016 ESC criteria of MINOCA (20%). Clinical presentation showed no difference in Killip-Kimball classification (K-K > I was 6.1% in MI with obstructive lesions vs 6.5% in MINOCA pts, p 0.897).  Chest pain (Angina) was more frequent in MI with obstructive lesions (82.8% vs 73.4%, p 0.027) and they also had more ST changes (ST elevation 41% vs 24%, p 0.001; ST descent 17% vs 8.3%, p 0.026). MINOCA pts had lower levels of troponine (troponine elevation less than 10 times the 99th percentile: 10.4% vs 26.6%, p <0.001). Left ventricular systolic dysfunction showed no difference neither in the % of pts with ejection fraction lower than 50% (MI with obstructive lesions:  32% vs MINOCA: 34.3%, p 0.659) nor in severe systolic dysfunction (ejection fraction lower than 30%: 4.9% in MI with obstructive lesions vs 7.4% in MINOCA pts, p 0.313). The average stay in MI pts with obstructive lesions was 12.6 days vs 8.9 days in MINOCA pts (p 0.274). Complications during hospital admission occurred in 17.6% of obstructive pts and in 13.8% of MINOCA pts (p 0.335). Only one MINOCA pts (0.9) died during admission compared to 3.4% of MI pts with obstructive lesions, being this result statistically non significant (p 0.213).


Although MINOCA pts have lower troponine levels and less severe alterations on the EKG, we did not find differences regarding left ventricular function and the rate of complications with hospital mortality that tended to be higher in patients with obstructive lesions.

This content is currently on FREE ACCESS, enjoy another 80 days of free consultation


Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are